SCHEDULE: Bios Entities Update Lantern Pharma Stake to 8.58%

Bios Capital Management and related entities report a combined 8.58% beneficial ownership in Lantern Pharma Inc. common stock.

Summary

• This is Amendment No. 5 to the Schedule 13D filing for Lantern Pharma Inc. (LPNT), updating previous beneficial ownership disclosures.
• Bios Capital Management, LP, Bios Advisors GP, LLC, Cavu Management, LP, Cavu Advisors, LLC, Leslie W. Kreis, and Aaron G.L. Fletcher each beneficially own 960,026 shares of Lantern Pharma Inc. common stock.
• This aggregate ownership represents 8.58% of the Issuer's outstanding common stock.
• The percentage is based on 11,184,423 outstanding shares, as reported in Lantern Pharma Inc.'s Form 10-Q filed on November 5, 2025.
• The shares are held through a complex structure involving various Bios funds (Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT) and their respective general partners.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update, primarily providing transparency on a significant, ongoing institutional ownership stake. The maintenance of an 8.58% stake by a sophisticated investor group can be seen as a vote of confidence, though the filing itself does not contain new operational or financial news.

Positives

• A significant institutional investor group maintains a substantial stake (8.58%) in Lantern Pharma Inc., indicating continued interest and potential long-term commitment.
• The filing provides transparency regarding the ownership structure of a major shareholder group, which is beneficial for market clarity.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are standard disclosures for significant ownership stakes, providing transparency into major investor positions within the biotechnology or pharmaceutical sector, where Lantern Pharma operates. This filing primarily details the structure of a specific investment group's holdings rather than broader industry trends.

Related Party Transactions

• The filing details a complex, hierarchical ownership structure where various Bios funds (Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT, BP Directors) are managed by general partners (Bios Equity Partners, Bios Equity Partners II).
• These general partners are in turn managed by Bios Capital Management, LP.
• Bios Capital Management, LP is managed by Bios Advisors GP, LLC and Cavu Management, LP.
• Cavu Advisors, LLC is the general partner of Cavu Management, LP.
• Leslie W. Kreis and Aaron G.L. Fletcher are individuals who control these entities (Mr. Kreis controls Cavu Advisors, Dr. Fletcher controls Bios Advisors), and are therefore deemed to have shared voting and dispositive power over the aggregate shares.
• This structure indicates a network of related entities and individuals acting in concert regarding their investment in Lantern Pharma Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of a significant institutional investor group, which can influence market perception and trading decisions.
• Management: Awareness of a large, organized shareholder group's stake.

Key Dates

Keywords

Lantern Pharma, LPNT, Schedule 13D, beneficial ownership, institutional investor, Bios Capital Management, Bios Equity Partners, common stock, SEC filing, ownership stake